Progyny, Inc. (NASDAQ:PGNY) Shares Sold by Polen Capital Management LLC

Polen Capital Management LLC cut its position in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 28.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 260,708 shares of the company's stock after selling 101,412 shares during the quarter. Polen Capital Management LLC owned 0.31% of Progyny worth $4,497,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC raised its holdings in Progyny by 341.4% during the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock worth $28,000 after purchasing an additional 1,246 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in Progyny by 108.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock worth $51,000 after purchasing an additional 1,526 shares during the last quarter. Caitlin John LLC raised its holdings in Progyny by 2,974.8% during the fourth quarter. Caitlin John LLC now owns 3,290 shares of the company's stock worth $57,000 after purchasing an additional 3,183 shares during the last quarter. SBI Securities Co. Ltd. acquired a new position in Progyny during the fourth quarter worth $74,000. Finally, Meeder Asset Management Inc. acquired a new position in Progyny during the third quarter worth $77,000. 94.93% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on PGNY shares. Bank of America boosted their price target on Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a report on Tuesday, February 11th. Canaccord Genuity Group boosted their price target on Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a report on Friday, February 28th. Finally, JPMorgan Chase & Co. boosted their price target on Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a report on Tuesday, January 28th. Nine equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $24.82.

Remove Ads

Insider Activity

In other news, Chairman David J. Schlanger purchased 150,000 shares of the stock in a transaction on Thursday, December 26th. The stock was purchased at an average price of $14.68 per share, with a total value of $2,202,000.00. Following the completion of the transaction, the chairman now owns 228,269 shares in the company, valued at approximately $3,350,988.92. The trade was a 191.65 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Peter Anevski purchased 209,500 shares of the stock in a transaction on Monday, December 23rd. The shares were purchased at an average cost of $14.48 per share, with a total value of $3,033,560.00. Following the transaction, the chief executive officer now owns 441,463 shares of the company's stock, valued at $6,392,384.24. This trade represents a 90.32 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company's stock.

Progyny Stock Down 0.1 %

Shares of NASDAQ:PGNY traded down $0.03 during midday trading on Thursday, reaching $21.68. The company's stock had a trading volume of 1,484,410 shares, compared to its average volume of 1,593,649. The firm has a market cap of $1.85 billion, a price-to-earnings ratio of 37.38, a price-to-earnings-growth ratio of 2.39 and a beta of 1.41. Progyny, Inc. has a 1 year low of $13.39 and a 1 year high of $38.98. The business has a 50 day moving average price of $21.80 and a 200 day moving average price of $18.61.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.